As researchers were starting to better understand the role of EGFR mutation as a driving force for some lung cancers, it was also being realized that an acquired resistance mutation, T790M, was responsible for many cases of treatment failure on first-generation agents [8]. This evidence concerns the gene EGFR and lung cancer.